AU2015209540B2 - Cellular platform for rapid and comprehensive T-cell immunomonitoring - Google Patents

Cellular platform for rapid and comprehensive T-cell immunomonitoring Download PDF

Info

Publication number
AU2015209540B2
AU2015209540B2 AU2015209540A AU2015209540A AU2015209540B2 AU 2015209540 B2 AU2015209540 B2 AU 2015209540B2 AU 2015209540 A AU2015209540 A AU 2015209540A AU 2015209540 A AU2015209540 A AU 2015209540A AU 2015209540 B2 AU2015209540 B2 AU 2015209540B2
Authority
AU
Australia
Prior art keywords
contiguous
sequence
cell
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015209540A
Other languages
English (en)
Other versions
AU2015209540A8 (en
AU2015209540A1 (en
Inventor
Steven C. Almo
Rodolfo CHAPARRO
Brandan S. Hillerich
Ronald D. Seidel Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of AU2015209540A1 publication Critical patent/AU2015209540A1/en
Publication of AU2015209540A8 publication Critical patent/AU2015209540A8/en
Application granted granted Critical
Publication of AU2015209540B2 publication Critical patent/AU2015209540B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2015209540A 2014-01-21 2015-01-21 Cellular platform for rapid and comprehensive T-cell immunomonitoring Ceased AU2015209540B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461929651P 2014-01-21 2014-01-21
US61/929,651 2014-01-21
PCT/US2015/012160 WO2015112541A2 (en) 2014-01-21 2015-01-21 Cellular platform for rapid and comprehensive t-cell immunomonitoring

Publications (3)

Publication Number Publication Date
AU2015209540A1 AU2015209540A1 (en) 2016-07-28
AU2015209540A8 AU2015209540A8 (en) 2016-08-18
AU2015209540B2 true AU2015209540B2 (en) 2021-05-13

Family

ID=53682115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015209540A Ceased AU2015209540B2 (en) 2014-01-21 2015-01-21 Cellular platform for rapid and comprehensive T-cell immunomonitoring

Country Status (11)

Country Link
US (2) US20170176435A1 (https=)
EP (1) EP3096774B1 (https=)
JP (1) JP6875126B2 (https=)
KR (1) KR102488477B1 (https=)
CN (1) CN106132428B (https=)
AU (1) AU2015209540B2 (https=)
BR (1) BR112016016937A8 (https=)
CA (1) CA2936352A1 (https=)
IL (1) IL246685B (https=)
SG (1) SG11201605632SA (https=)
WO (1) WO2015112541A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894511C (en) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
US11407806B2 (en) 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
CN107099603A (zh) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 肿瘤免疫t细胞检测试剂盒和检测方法
EP3678691A4 (en) * 2017-09-07 2021-06-09 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
IL285534B2 (en) * 2019-02-12 2025-04-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
JP7658584B2 (ja) * 2019-05-23 2025-04-08 マサチューセッツ インスティテュート オブ テクノロジー リガンドの発見およびレトロウイルス表面ディスプレーを介した遺伝子送達
US20230126784A1 (en) * 2020-03-06 2023-04-27 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
EP4281569A4 (en) * 2021-01-25 2025-04-02 The Regents Of The University Of California Methods and compositions for labeling and selecting antigen-specific T cells
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
WO2023076994A1 (en) * 2021-10-27 2023-05-04 The Penn State Research Foundation Universal stem cell and uses thereof
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1287363A2 (en) * 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
KR20040032105A (ko) * 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
AU2003901876A0 (en) * 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
EP1889851A1 (en) * 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
RU2015125639A (ru) * 2012-11-30 2017-01-10 Роше Гликарт Аг Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i

Also Published As

Publication number Publication date
JP2017506882A (ja) 2017-03-16
WO2015112541A8 (en) 2016-09-09
EP3096774A2 (en) 2016-11-30
IL246685B (en) 2020-03-31
KR20170002366A (ko) 2017-01-06
KR102488477B1 (ko) 2023-01-13
BR112016016937A2 (pt) 2017-08-08
CN106132428A (zh) 2016-11-16
AU2015209540A8 (en) 2016-08-18
EP3096774A4 (en) 2017-09-06
WO2015112541A2 (en) 2015-07-30
WO2015112541A3 (en) 2015-12-03
CA2936352A1 (en) 2015-07-30
SG11201605632SA (en) 2016-08-30
IL246685A0 (en) 2016-08-31
US20230052675A1 (en) 2023-02-16
JP6875126B2 (ja) 2021-05-19
US20170176435A1 (en) 2017-06-22
CN106132428B (zh) 2021-08-06
BR112016016937A8 (pt) 2018-12-18
AU2015209540A1 (en) 2016-07-28
EP3096774B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
US20230052675A1 (en) Cellular platform for rapid and comprehensive t-cell immunomonitoring
EP3661528B1 (en) Reagents for expanding cells expressing recombinant receptors
US12221465B2 (en) Signaling and antigen-presenting bifunctional receptors (SABR)
AU2018201812B2 (en) Methods for high throughput receptor:ligand identification
Truscott et al. Disulfide bond engineering to trap peptides in the MHC class I binding groove
EP3851450B1 (en) Chimeric antigen receptors and methods of use
Wen et al. Cell surface display of functional human MHC class II proteins: yeast display versus insect cell display
Koo et al. Defining T cell receptor repertoires using nanovial-based affinity and functional screening
KR20260016919A (ko) 제시된 hpv16-, mart1-, cmv-, ebv-, 또는 인플루엔자-펩티드에 결합하는 t 세포 수용체
CN111826398A (zh) 用于活细胞间膜蛋白展示和相互作用检测的工程质粒系统
HK40111624A (zh) 评定mhc-肽-tcr相互作用和动力学的细胞测定和方法
HK1218144B (zh) 高通量受体:配体鉴定方法
HK1239704B (en) Chimeric antigen receptors and methods of use
HK1239704A1 (en) Chimeric antigen receptors and methods of use

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 30 , NO 30 , PAGE(S) 4506 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., APPLICATION NO. 2015209540, UNDER INID (72) CORRECT THE CO-INVENTOR TO SEIDEL III, RONALD D.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired